Start date: 2002-01-01, End date: 2004-12-31
INHERINET aims to develop novel, safe and curative treatments based on therapeutic gene transfer into antilogous (i.e., patient-derived) haematopoietic stem cells for selected example hereditary diseases, which include immunodeficiency's, mucopolysaccharidosis VI, Diamond-Blac...
Programme: FP5-LIFE QUALITY
Record Number: 64550
Last updated on: 2005-04-12